Cargando…

Pogostone inhibits the activity of CYP3A4, 2C9, and 2E1 in vitro

CONTEXT: Pogostone possesses various pharmacological activities, which makes it widely used in the clinic. Its effect on the activity of cytochrome P450 enzymes (CYP450s) could guide its clinical combination. OBJECTIVE: To investigate the effect of pogostone on the activity of human CYP450s. MATERIA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Guiying, Zhang, Yanping, Ma, Xianjie, Yang, Xin, Cai, Yuyan, Yin, Wenli
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8871619/ https://www.ncbi.nlm.nih.gov/pubmed/33915070 http://dx.doi.org/10.1080/13880209.2021.1917630

Ejemplares similares

T cell inhibition by pogostone from Pogostemon cablin (Blanco) Benth: In vitro and in vivo immunosuppressive analysis
por: Su, Jiyan, et al.
Publicado: (2017)

Protective Effect of Pogostone on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis via Inhibition of T Helper Cell
por: Su, Jiyan, et al.
Publicado: (2017)

Pogostone Enhances the Antibacterial Activity of Colistin against MCR-1-Positive Bacteria by Inhibiting the Biological Function of MCR-1
por: Xie, Shengnan, et al.
Publicado: (2022)

Functional characterization of the defective CYP2C9 variant CYP2C9*18
por: Liu, Jian, et al.
Publicado: (2021)

Determinants of the Inhibition of DprE1 and CYP2C9 by Antitubercular Thiophenes
por: Liu, Renhe, et al.
Publicado: (2017)

Alpinetin suppresses CYP3A4, 2C9, and 2E1 activity in vitro
por: Song, Hongming, et al.
Publicado: (2022)

In vitro evaluation of the pogostone effects on the expression of PTEN and DACT1 tumor suppressor genes, cell cycle, and apoptosis in ovarian cancer cell line
por: Homayoun, Mansour, et al.
Publicado: (2022)

Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?
por: Yasar, Umit
Publicado: (2018)

Noncompetitive inhibition of human CYP2C9 in vitro by a commercial Rhodiola rosea product
por: Thu, Ole Kristian Forstrønen, et al.
Publicado: (2017)

In vitro inhibitory effect of obtusofolin on the activity of CYP3A4, 2C9, and 2E1
por: Liu, Na, et al.
Publicado: (2021)

A Systematically Combined Genotype and Functional Combination Analysis of CYP2E1, CYP2D6, CYP2C9, CYP2C19 in Different Geographic Areas of Mainland China – A Basis for Personalized Therapy
por: Wu, Zhenqiang, et al.
Publicado: (2013)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

Global variation in CYP2C8–CYP2C9 functional haplotypes
por: Speed, William C, et al.
Publicado: (2009)

Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals
por: Wang, Xiaoxing, et al.
Publicado: (2022)

Identification and drug metabolic characterization of four new CYP2C9 variants CYP2C9*72-*75 in the Chinese Han population
por: Zhao, Fang-Ling, et al.
Publicado: (2022)

Characterization of a Cytosolic Acyl-Activating Enzyme Catalyzing the Formation of 4-Methylvaleryl-CoA for Pogostone Biosynthesis in Pogostemon Cablin
por: Chen, Jing, et al.
Publicado: (2021)

Effect of GLPG1205, a GPR84 Modulator, on CYP2C9, CYP2C19, and CYP1A2 Enzymes: In Vitro and Phase 1 Studies
por: Desrivot, Julie, et al.
Publicado: (2021)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism
por: Tang, Peng-fei, et al.
Publicado: (2020)

Effects of CYP2C19 variants on the metabolism of tapentadol in vitro
por: Xu, Ren-ai, et al.
Publicado: (2022)

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
por: Tan, Ming‐Liang, et al.
Publicado: (2017)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Identification and in vitro functional assessment of 10 CYP2C9 variants found in Chinese Han subjects
por: Zhang, Qing, et al.
Publicado: (2023)

CYP2C8 and CYP2C9 mRNA expression profile in the human fetus
por: Johansson, Maria, et al.
Publicado: (2014)

CYP2C9 and CYP2C19: Deep Mutational Scanning and Functional Characterization of Genomic Missense Variants
por: Zhang, Lingxin, et al.
Publicado: (2020)

The Evaluation of CYP2D6, CYP2C9, CYP2C19, and CYP2B6 Phenoconversion in Post-Mortem Casework: The Challenge of Forensic Toxicogenetics
por: Giorgetti, Arianna, et al.
Publicado: (2023)

Metabolic inhibition of meloxicam by specific CYP2C9 inhibitors in Cunninghamella blakesleeana NCIM 687: in silico and in vitro studies
por: Prasad, G. Shyam, et al.
Publicado: (2016)

The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals
por: Haeggström, Sigrid, et al.
Publicado: (2022)

Combination Analysis in Genetic Polymorphisms of Drug-Metabolizing Enzymes CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A5 in the Japanese Population
por: Ota, Tomoko, et al.
Publicado: (2015)

Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy
por: Lakhan, Ram, et al.
Publicado: (2011)

Association of CYP2C9 Genetic Variants with Vitiligo
por: Alzolibani, Abdullateef A., et al.
Publicado: (2014)

Pharmacogenomics of CYP2C9: Functional and Clinical Considerations(†)
por: Daly, Ann K., et al.
Publicado: (2017)

Relevance of CYP2C9 Function in Valproate Therapy
por: Monostory, Katalin, et al.
Publicado: (2019)

Estudio de las variantes alélicas CYP2C9*2 y CYP2C9*3 en muestras de población mestiza peruana
por: Alvarado, Ángel Tito, et al.
Publicado: (2019)

The Effect of UGT1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children
por: Pavlovic, Dimitrije, et al.
Publicado: (2020)

Clinical pharmacokinetics of ketoprofen enantiomers in wild type of Cyp 2c8 and Cyp 2c9 patients with rheumatoid arthritis
por: Główka, Franciszek, et al.
Publicado: (2011)

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
por: Fohner, Alison E., et al.
Publicado: (2020)

Short‐ and long‐term effects of body weight, calorie restriction and gastric bypass on CYP1A2, CYP2C19 and CYP2C9 activity
por: Kvitne, Kine Eide, et al.
Publicado: (2022)

Evaluation of Drug–Drug Interactions of Rucaparib and CYP1A2, CYP2C9, CYP2C19, CYP3A, and P‐gp Substrates in Patients With an Advanced Solid Tumor
por: Xiao, Jim J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v1n71cid7ufmap954636mkbdna